RxDoctor Payments Data

William Swoger

Pulmonary Disease · Dover, OHNPI 1689624256

Payments from drug & device makers

$1,077in general payments, 2019–2025

Across 38 payments — averaging $28.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$242
  • United Therapeutics Corporation$225
  • Sanofi$161
  • Boston Scientific$101
  • Inspire Medical Systems, Inc.$56
  • Insmed, Inc.$51
  • plus $241 from 10 others

What the payments were for

  • Food & beverage$1,04497%
  • Education$343%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,077 in reported general payments places this provider in the 40th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$138,514
Medicare patients
575
Services billed
1,466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter676$483,989
Breztri AerosphereBudesonide/Glycopyr/Formoterol321$227,519
OfevNintedanib Esylate16$207,722
Dupixent PenDupilumab37$163,544
Breo ElliptaFluticasone/Vilanterol118$57,436
Advair HfaFluticasone Propion/Salmeterol73$48,056
DuleraMometasone/Formoterol109$44,145
EliquisApixaban52$38,549
Spiriva RespimatTiotropium Bromide58$38,511
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr50$29,096
SymbicortBudesonide/Formoterol Fumarate73$20,056
Fluticasone-SalmeterolFluticasone Propion/Salmeterol137$18,941
Combivent RespimatIpratropium/Albuterol Sulfate35$18,648
Incruse ElliptaUmeclidinium Bromide35$14,318
Albuterol Sulfate HfaAlbuterol Sulfate485$13,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$18$591,471897 claims
AstraZenecaBreztri Aerosphere, Symbicort$242$247,575394 claims
MerckDulera$29$44,145109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Dover

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →